FDA has partnered with Flatiron Health to assess the use of real-real world data to demonstrate the safety and efficacy of cancer immunotherapies.
Gilead names a COO, Sanofi loses a top exec and the management churn continues at Valeant. Plus more hirings, firings and retirings throughout the industry.
The injectable FX006 is based on one of the oldest treatment measures in place for osteoarthritis: a steroid shot right into a sore joint.
The FDA handed down a major shock to AstraZeneca yesterday when it rejected its key hyperkalemia drug ZS-9, leaving potential rival Relypsa’s shares to jump in…
Clinicians looking for a reliable, controlled method to treat a host of recovering opioid addicts will now have a new resource in the armamentarium.
It’s a veritable free-for-all market for CROs as yet another contract research group--this time Bioclinica--is said to be seeking a major sale.
A few weeks after the FDA slapped a clinical hold on GlaxoSmithKline’s late-stage work on an experimental drug for a rare cardiac condition, the pharma giant…
A trio of Israeli biotechs have completed the initial filings for IPOs to raise up to $130 million each--but are holding off until demand picks up.
Bavarian Nordic has posted top-line data from a Phase I trial of its respiratory syncytial virus vaccine, setting it up to start larger study later this year.
A startup has picked up a Merck Serono castoff, signed up the R&D chief who axed the drug and set about turning it into a multiple myeloma combo treatment.